Novo Nordisk Company Profile

✉ Email this page to a colleague

NOVO NORDISK has five approved drugs.

There are four US patents protecting NOVO NORDISK drugs.

There are eighty-three patent family members on NOVO NORDISK drugs in twenty-nine countries and one hundred and one supplementary protection certificates in sixteen countries.

International Patents:	83
US Patents:	4
Tradenames:	5
Ingredients:	4
NDAs:	5
Patent Litigation for Novo Nordisk:	See patent lawsuits for Novo Nordisk

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes	9,265,893*PED	⤷ Subscribe			Y	⤷ Subscribe
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-001	Mar 26, 1999		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes	9,968,659*PED	⤷ Subscribe			Y	⤷ Subscribe
Novo Nordisk	GLUCAGEN	glucagon hydrochloride	POWDER;INTRAMUSCULAR, INTRAVENOUS	020918-001	Jun 22, 1998		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-001	Jun 23, 2008	6,677,358	⤷ Subscribe
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	RE41956*PED	⤷ Subscribe
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,004,297	⤷ Subscribe
Novo Nordisk Inc	PRANDIMET	metformin hydrochloride; repaglinide	TABLET;ORAL	022386-002	Jun 23, 2008	6,677,358	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	1 mg/500 mg and 2 mg/500 mg	➤ Subscribe	2009-04-09
➤ Subscribe	Injection	18 mg/3 mL prefilled syringe	➤ Subscribe	2016-12-12
➤ Subscribe	Vaginal Tablets	10 mcg	➤ Subscribe	2013-01-02

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
China	108778317	⤷ Subscribe
Japan	5634068	⤷ Subscribe
Russian Federation	2421238	⤷ Subscribe
World Intellectual Property Organization (WIPO)	2005049061	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	C300357	Netherlands	⤷ Subscribe	PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
2498758	PA2020003,C2498758	Lithuania	⤷ Subscribe	PRODUCT NAME: METFORMINO HIDROCHLORIDAS; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111
2597103	2017/015	Ireland	⤷ Subscribe	PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912
1261586	2012C/016	Belgium	⤷ Subscribe	PRODUCT NAME: UNE COMBINAISON DE PRODUITS DE SAXAGLIPTINE ET DE METFORMINE AINSI QUE TOUT SELS PHARMACEUTIQUEMENT ACCEPTABLES, DONT LES SELS DE CHLORHYDRATE DE SAXAGLIPTINE ET DE METFORMINE; AUTHORISATION NUMBER AND DATE: EU/1/11/731/001 20111128
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.